Thermo Fisher Scientific Inc. $TMO Shares Sold by Loring Wolcott & Coolidge Fiduciary Advisors LLP MA

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA lessened its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.6% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 539,623 shares of the medical research company’s stock after selling 3,064 shares during the quarter. Thermo Fisher Scientific makes up about 3.0% of Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings, making the stock its 9th biggest holding. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in Thermo Fisher Scientific were worth $336,676,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of the business. Brighton Jones LLC boosted its position in Thermo Fisher Scientific by 28.9% during the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock worth $2,293,000 after acquiring an additional 988 shares during the period. Revolve Wealth Partners LLC grew its position in Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after purchasing an additional 20 shares in the last quarter. Darwin Wealth Management LLC purchased a new stake in Thermo Fisher Scientific in the 2nd quarter worth approximately $170,000. Raymond James Financial Inc. increased its stake in shares of Thermo Fisher Scientific by 7.4% in the second quarter. Raymond James Financial Inc. now owns 778,822 shares of the medical research company’s stock worth $315,781,000 after acquiring an additional 53,542 shares during the last quarter. Finally, California State Teachers Retirement System grew its stake in Thermo Fisher Scientific by 0.4% in the second quarter. California State Teachers Retirement System now owns 602,031 shares of the medical research company’s stock valued at $244,099,000 after purchasing an additional 2,262 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling

In other news, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction on Monday, February 9th. The stock was sold at an average price of $541.20, for a total transaction of $216,480.00. Following the sale, the executive vice president owned 20,752 shares in the company, valued at approximately $11,230,982.40. This represents a 1.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Marc N. Casper sold 5,000 shares of the firm’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total value of $2,562,000.00. Following the completion of the sale, the chief executive officer owned 123,925 shares of the company’s stock, valued at approximately $63,499,170. This trade represents a 3.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific News Summary

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Q1 beat on top‑ and bottom‑line — Revenue of $11.01B (+6.2% YoY) and non‑GAAP EPS of $5.44 exceeded Street estimates (revs ~$10.86B; EPS ~$5.25). This confirms solid core demand and margin resilience. Thermo Fisher Scientific Reports First Quarter 2026 Results
• Positive Sentiment: Strength in growth segments — Management highlighted lab products and biopharma services as growth drivers that offset weaker areas, supporting recurring revenue and higher‑margin service exposure. Thermo Fisher posts quarterly results beat as lab products, biopharma services grow
• Positive Sentiment: Analyst sentiment remains constructive — Consensus analyst rating is around “Moderate Buy,” indicating institutional expectations for continued earnings growth. Thermo Fisher Given Consensus Rating of “Moderate Buy”
• Neutral Sentiment: Company press release and detailed metrics available — The official release reiterates results, margins and KPIs for the quarter for investors wanting primary source detail. View Press Release
• Neutral Sentiment: Long‑term TAM and digital lab trends support growth — Market research highlights growth in cloud ELN and microbiology testing markets that play to Thermo Fisher’s product and services mix. Global Cloud ELN Service Market | Thermo Fisher
• Negative Sentiment: Shares slipped in premarket despite the beat — Immediate market reaction suggests investors focused on mixed segment performance, profit‑taking after recent gains, or expectations for stronger beats. Thermo Fisher slips in premarket despite beating Q1 forecasts
• Negative Sentiment: Softness in analytical instruments and specialty diagnostics may concern investors — Reuters flagged weakness in those areas, which could pressure growth if persistent. Thermo Fisher posts quarterly results beat as lab products, biopharma services grow
• Negative Sentiment: Technical and valuation considerations — TMO trades below its 200‑day SMA and carries a mid‑to‑high P/E (~29), which can amplify downside on mixed prints as investors rotate to cheaper or higher‑momentum names.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on TMO. Wells Fargo & Company set a $683.00 price target on shares of Thermo Fisher Scientific in a research note on Friday, January 30th. Weiss Ratings restated a “hold (c)” rating on shares of Thermo Fisher Scientific in a report on Wednesday, April 8th. Citigroup increased their price objective on Thermo Fisher Scientific from $660.00 to $685.00 and gave the company a “buy” rating in a report on Friday, January 30th. Barclays lowered their price target on Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating on the stock in a report on Tuesday, April 14th. Finally, TD Cowen cut their target price on shares of Thermo Fisher Scientific from $696.00 to $683.00 and set a “buy” rating for the company in a research report on Friday, January 30th. One research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and a consensus price target of $631.25.

Thermo Fisher Scientific Stock Performance

Thermo Fisher Scientific stock opened at $515.04 on Thursday. The firm has a market capitalization of $191.40 billion, a P/E ratio of 29.03, a P/E/G ratio of 2.72 and a beta of 0.97. The stock has a fifty day moving average price of $500.69 and a two-hundred day moving average price of $550.56. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $643.99. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.89 and a quick ratio of 1.53.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, topping the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a net margin of 15.05% and a return on equity of 16.92%. The business had revenue of $11.01 billion for the quarter, compared to analyst estimates of $10.86 billion. As a group, analysts anticipate that Thermo Fisher Scientific Inc. will post 24.68 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, April 15th. Stockholders of record on Friday, March 13th were paid a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. The ex-dividend date was Friday, March 13th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.60%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.